secwatch.observer — SEC 8-K summary
======================================

Issuer:     OCULAR THERAPEUTIX, INC (OCUL)
CIK:        0001393434
Form:       8-K
Filed at:   2024-08-07T23:59:59+00:00
Accession:  0001104659-24-086535
Event type: earnings
Sentiment:  neutral
Materiality: 0.75
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Ocular Therapeutix Q2 net loss $(43.8)M; AXPAXLI SOL-R accepted as pivotal trial
--------------------------------------------------------------------------------

- Net loss of $(43.8)M ($(0.26)/share) vs $(20.7)M ($(0.26)/share) in Q2 2023; revenue $16.4M (+8.3% YoY).
- Cash $459.7M as of June 30, 2024; expected to fund operations into 2028.
- FDA confirmed SOL-R repeat dosing study (Phase 3 wet AMD) is appropriate as second registrational trial; ~825 subjects to be randomized.
- SOL-1 enrollment accelerating: 151 subjects enrolled as of June 7, 2024, 60 active sites.
- HELIOS Phase 1 NPDR data showed DRSS improvement; no intraocular inflammation; presented at ASRS.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1393434/000110465924086535/0001104659-24-086535-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1393434/000110465924086535/tm2420962d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-24-086535

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer